Effect of propranolol on left ventricular relaxation in hypertrophic cardiomyopathy: An echographic study

doi:10.1016/0002-8703(85)90357-6

American Heart Journal

Volume 109, Issue 6, June 1985, Pages 1311-1316

https://doi.org/10.1016/0002-8703(85)90357-6 Get rights and content

Abstract

Many authors have shown that hypertrophic cardiomyopathy (HCM) is often associated with diastolic abnormalities. The purpose of this study was to determine the effect of propranolol on left ventricular isovolumic relaxation time (IVRT) measured by echocardiography in 20 patients with hypertrophic cardiomyopathy under basal conditions and under increasing doses of propranolol (160 mg, 320 mg, and 480 mg per day) and in two control groups, 10 patients with aortic stenosis, and 10 normal subjects. IVRT was less than 50 msec in all normal subjects, while it was always above this limit in aortic stenosis (77 msec ± 8, p < 0.001), and in hypertrophic cardiomyopathy (94 msec ± 19, p < 0.001), with also a significant difference between these two last groups (p < 0.01). Under increasing doses of propranolol, relaxation time often shortens gradually until 50 msec or less. These results show an improvement in left ventricular relaxation dependent on the propranolol dosage and often a normalization at high dosages.

References (33)

MS Gotsman et al.
Left ventricular volumes and compliance in hypertrophic cardiomyopathy
Chest
(1974)
P Hanrath et al.
Left ventricular relaxation and filling pattern in different forms of left ventricular hypertrophy: An echocardiographic study
Am J Cardiol
(1980)
MI Canedo et al.
Therapy of hypertrophic cardiomyopathy: Medical or surgical? Clinical and physiopathologic considerations
Am J Cardiol
(1981)
T Hardarson et al.
Prognosis and mortality of hypertrophic obstructive cardiomyopathy
Lancet
(1973)
A Benchimol et al.
The value of the apexcardiogram as a reference tracing in phonocardiography
Am Heart J
(1961)
DG Oakley et al.
Significance of abnormal electrocardiograms in highly trained athletes
Am J Cardiol
(1982)
JE Sanderson et al.
Left ventricular filling in hypertrophic cardiomyopathy; an angiographic study
Br Heart J
(1977)
JE Sanderson et al.
Left ventricular relaxation and filling in hypertrophic cardiomyopathy; an echocardiographic study
Br Heart J
(1978)
N Kolev et al.
Use of the first derivative of apexcardiogram and echocardiogram dimensions for assessing left ventricular relaxation and mean velocity of circumferential fibre lengthening in cardiomyopathy
Eur Heart J
(1981)
MG St-John Sutton et al.
Echocardiographic assessment of left ventricular filling and septal and posterior wall dynamics in idiopathic hypertrophic subaortic stenosis
Circulation
(1978)

MM Webb-Peploe et al.

Cardioselective beta blockade in hypertrophic cardiomyopathy

Acta Cardiol

(1972)

BS Lewis et al.

Haemodynamic effects of beta blockade in hypertrophic cardiomyopathy using sectral (acebutolol; M × B 17803 A)

Cardiovasc. Res

(1974)

PJB Hubner et al.

Double-blind trial of propranolol and practolol in hypertrophic cardiomyopathy

Br Heart

(1973)

C Saenz de la Calzada et al.

Effect of acute administration of propranolol on ventricular function in hypertrophic obstructive cardiomyopathy, measured by non-invasive techniques

Br Heart J

(1976)

RH Swanton et al.

Hemodynamic studies of beta-blockade in patients with hypertrophic obstructive cardiomyopathy

Eur J Cardiol

(1977)

BH Lorell et al.

Modification of abnormal left ventricular diastolic properties by niefedipine in patients with hypertrophic cardiomyopathy

Circulation

(1982)

Cited by (47)

Effect of metoprolol in hypertrophic obstructive cardiomyopathy patients after alcohol septal ablation
2023, IJC Heart and Vasculature
The use of beta-blockers in hypertrophic obstructive cardiomyopathy (HOCM) patients after alcohol septal ablation (ASA) lacks data support. We aimed to evaluate the effect of metoprolol on exercise capacity, hemodynamic and laboratory parameters, and quality of life in HOCM patients after ASA.
This was a prospective randomized single-center open-label crossover trial in 21 HOCM patients after ASA. Patients received metoprolol and no beta-blocker for two periods of three months. The endpoints were: peak oxygen uptake (pVO₂), maximal left ventricular outflow tract (LVOT) pressure gradient at peak exercise, a ratio of mitral peak velocity of the early filling (E) to early diastolic mitral annular velocity (e′) (E/e′) at rest, Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score, and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) plasmatic concentration.
No significant association was found between the treatment and any of the endpoints in the assessed patients: 1) pVO₂ (19.5 ± 5.3 ml/kg/min vs. 19.4 ± 4.1 ml/kg/min, p = 0.90), 2) exercise-induced pressure gradient in LVOT 32 ± 37 mmHg vs. 32 ± 30 mmHg, p = 0.84, 3) E/e′ ratio at rest (11 ± 4 vs. 10 ± 4, p = 0.23), 4) KCCQ overall summary score (78 ± 11 vs. 77 te ± 15, p = 0.56), 5) NT-proBNP (215 pg/ml [121–333] vs. 153 pg/ml [102–228], p = 0.19).
In HOCM patients after successful ASA, metoprolol treatment did not improve exercise capacity, hemodynamic and laboratory parameters, or quality of life.
Neonatal Myocardial Infarction in Association With Gestational Diabetes
2021, Canadian Journal of Cardiology
Fetal and neonatal hypertrophic cardiomyopathy is a complication of gestational diabetes and usually follows a benign course. In this report, we present a rare case of a newborn of a diabetic mother with severe ventricular hypertrophy who developed myocardial infarction confirmed by elevated cardiac enzymes, electrocardiographic changes, and subendocardial ischemia on cardiac magnetic resonance imaging. Follow-up revealed complete functional myocardial recovery with normalisation of ventricular systolic and diastolic functions on serial echocardiograms.
La cardiomyopathie hypertrophique fœtale et néonatale est une complication du diabète gestationnel et connaît généralement une évolution bénigne. Dans ce rapport, nous présentons le cas rare d'un nouveau-né de mère diabétique, présentant une hypertrophie ventriculaire sévère, qui a développé un infarctus du myocarde confirmé par des taux d'enzymes cardiaques élevés, des changements à l'ECG et une ischémie sous-endocardique identifiée par l'imagerie par résonance magnétique cardiaque. Le suivi a révélé un rétablissement fonctionnel complet du myocarde avec normalisation des fonctions systoliques et diastoliques ventriculaires sur une série d'échocardiogrammes.
2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2021, Journal of Thoracic and Cardiovascular Surgery
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020, Journal of the American College of Cardiology
This executive summary of the hypertrophic cardiomyopathy clinical practice guideline provides recommendations and algorithms for clinicians to diagnose and manage hypertrophic cardiomyopathy in adult and pediatric patients as well as supporting documentation to encourage their use.
A comprehensive literature search was conducted from January 1, 2010, to April 30, 2020, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Collaboration, Agency for Healthcare Research and Quality reports, and other relevant databases.
Many recommendations from the earlier hypertrophic cardiomyopathy guidelines have been updated with new evidence or a better understanding of earlier evidence. This summary operationalizes the recommendations from the full guideline and presents a combination of diagnostic work-up, genetic and family screening, risk stratification approaches, lifestyle modifications, surgical and catheter interventions, and medications that constitute components of guideline directed medical therapy. For both guideline-directed medical therapy and other recommended drug treatment regimens, the reader is advised to follow dosing, contraindications and drug-drug interactions based on product insert materials.
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020, Journal of the American College of Cardiology
Hypertrophic Cardiomyopathy
2020, Diastology: Clinical Approach to Heart Failure with Preserved Ejection Fraction
In hypertrophic cardiomyopathy (HCM), macroscopic and microscopic alterations in myocardial structure (myocardial hypertrophy, fiber disarray, increased loose connective tissue, and fibrosis) and abnormalities of the coronary microvasculature interfere with both myocyte force generation and myocardial relaxation. The mutations related to HCM result in the production of abnormal myocardial sarcomeric proteins that have altered contraction and relaxation characteristics. These include changes in the affinity between the various contractile proteins, changes in the sensitivity to Ca⁺², the efficiency of energy utilization (from ATP), and its expenditure. During stress, ischemia-induced diastolic dysfunction occurs at higher heart rates, reducing the diastolic filling period, resulting in increased intracavitary pressures aggravating subendocardial ischemia further. This is compounded by reduced left ventricular (LV) diastolic distensibility during exercise. Dyspnea is a common symptom, predominantly related to the presence of diastolic dysfunction and LV outflow tract (LVOT) obstruction. Worsening dyspnea may be precipitated by either the acute onset of atrial fibrillation or more insidiously by the development of LV systolic dysfunction. Echocardiography is the imaging modality of choice for the assessment of diastolic function in HCM, although accurate classification of diastolic function grade presents a challenge due to the compounding effects of LVOT obstruction and mitral regurgitation. Myocardial mechanics (assessment of strain rate, apical reverse rotation, and left atrial phasic volumes) may aid in diastolic functional assessment and be correlated with symptoms. Medical and invasive (septal reduction) therapy of LVOT obstruction may also improve diastolic function in patients with obstructive HCM.

View all citing articles on Scopus

View full text

Effect of propranolol on left ventricular relaxation in hypertrophic cardiomyopathy: An echographic study

Abstract

Chest

Am J Cardiol

Am J Cardiol

Lancet

Am Heart J

Am J Cardiol

Left ventricular filling in hypertrophic cardiomyopathy; an angiographic study

Br Heart J

Left ventricular relaxation and filling in hypertrophic cardiomyopathy; an echocardiographic study

Br Heart J

Use of the first derivative of apexcardiogram and echocardiogram dimensions for assessing left ventricular relaxation and mean velocity of circumferential fibre lengthening in cardiomyopathy

Eur Heart J

Echocardiographic assessment of left ventricular filling and septal and posterior wall dynamics in idiopathic hypertrophic subaortic stenosis

Circulation

Cardioselective beta blockade in hypertrophic cardiomyopathy

Acta Cardiol

Haemodynamic effects of beta blockade in hypertrophic cardiomyopathy using sectral (acebutolol; M × B 17803 A)

Cardiovasc. Res

Double-blind trial of propranolol and practolol in hypertrophic cardiomyopathy

Br Heart

Effect of acute administration of propranolol on ventricular function in hypertrophic obstructive cardiomyopathy, measured by non-invasive techniques

Br Heart J

Hemodynamic studies of beta-blockade in patients with hypertrophic obstructive cardiomyopathy

Eur J Cardiol

Modification of abnormal left ventricular diastolic properties by niefedipine in patients with hypertrophic cardiomyopathy

Circulation